Radiolabelling and Biological Assessment of 99mTc-Mebeverine as a Possible Tracer for Solid Tumor Diagnosis

Essam, Heba M.; Refaye, Marwa S.; El-Sharawy, Dina M.

doi:10.21608/ejrsa.2021.92163.1122

Radiolabelling and Biological Assessment of 99mTc-Mebeverine as a Possible Tracer for Solid Tumor Diagnosis

Document Type : Original Article

Authors

¹ Cyclotron Project, Nuclear Research Centre, Egyptian Atomic Energy Authority, Cairo, Egypt

² Biological Application Department, Nuclear Research Center, Egyptian Atomic Energy Authority, Cairo, Egypt

³ Radioactive isotopes and generators department, Hot Lab. Center, Egyptian Atomic Energy Authority, Cairo, Egypt

⁴ Labeled Compounds Department, Hot Lab. Center, Egyptian Atomic Energy Authority, Cairo, Egypt

10.21608/ejrsa.2021.92163.1122

Abstract

NUCLEAR medicine is one the most important fields to inspect and treat tumors by radiation or by introducing labeled radiopharmaceuticals, which are in the spot of our interest. In this study, the authors investigated the possibility of using mebeverine as a solid tumor marker. Mebeverine was labeled with Technetium (^99mTc-Meb) reaching a radiochemical yield (RCY) of 97% via a reduction reaction using SnCl₂. The tracer showed a high stability in the serum for 12 hours which is essential to avoid any undesired accumulations in the non-target organs. Its bioevaluation in normal and induced tumored mice was performed to identify the capability of the use of the tracer for the diagnosis of solid tumors. The uptake by the tumor was 14.2% after 30 min of injection and increased to 18.5%, viewing a decline after 3 hours, this could be attributed to that washout to the tumored muscle extravasation. Tumored /Non-Tumored (T/NT) ratio was applied, the ratio reached 3.14 which shows the selectivity of ^99mTc-Meb to the solid tumor induced in the right thigh.

Keywords